Through discovery and innovation, we create solutions to understand disease risk and find new treatments to help people live longer and healthier lives.
InterGenetics® Technology Changes The Way We Treat Disease
InterGenetics® is a personalized medicine company focused on molecular diagnostics and targeted therapy for cancer. An innovator in the frontier of genetic medicine, InterGenetics® research discovered CombiSNP®, proprietary gene combinations and DNA assessment technology leading to OncoVue®, the first broad genetic predictive test for breast cancer applicable to all women.
OncoVue® Breast Cancer Risk Test
InterGenetics® has now developed a breast cancer risk test called OncoVue® that is now offered in multiple clinics across the country. The OncoVue® Test, which has the potential to indicate a woman's risk of developing breast cancer years before the onset of the disease, is performed in our own CLIA-certified, cytogenetics laboratory along with other molecular diagnostic tests through a SNP genotyping platform.
Targeted Cancer Therapeutics
Traditionally, diagnostic and therapeutic development programs had totally different development processes and had little to do with each other. Genetic medicine, personalized medicine and gene therapy have begun to align themselves where the value of one is directly tied to the value of the other. InterGenetics® has identified a particular gene that is now in preclinical studies as a tumor suppressor and has been linked to a number of different types of cancers, such as lung, brain, pancreas and breast.